CO5540307A2 - Derivados de piperidina utiles como moduladores de la activi dad del receptor de quimoquina - Google Patents
Derivados de piperidina utiles como moduladores de la activi dad del receptor de quimoquinaInfo
- Publication number
- CO5540307A2 CO5540307A2 CO03112957A CO03112957A CO5540307A2 CO 5540307 A2 CO5540307 A2 CO 5540307A2 CO 03112957 A CO03112957 A CO 03112957A CO 03112957 A CO03112957 A CO 03112957A CO 5540307 A2 CO5540307 A2 CO 5540307A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- hydroxy
- halogen
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- -1 nitro, hydroxy Chemical group 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
Abstract
1.- Un compuesto de formula (I):en donde:T es C(O) o S(O)2;W es C(O) o S(O)2;X es CH2, O o NH;Y es CR5 o N;R1 es arilo opcionalmente substituido o heterociclilo opcionalmente substituido;R2 es hidrógeno o alquiloC1-6;R3 es hidrógeno o alquiloC1-6 opcionalmente substituido;R4 es alquilo, arilo opcionalmente substituido, aralquilo opcionalmente substituido o heterociclilo opcionalmente substituido;R5 es hidrógeno o alquiloC1-6;en donde las mitades aril y heterociclil precedentes están opcionalmente sustituidas por: halógeno, ciano, nitro, hidroxi, oxo, S(O)pR25, OC(O)NR6R7, NR8R9, NR10C(O)R11, NR12C(O)NR13R14, S(O)2NR15R16, NR17S(O)2R18, C(O)NR19R20, C(O)R21, CO2R22, NR23CO2R24, alquiloC1-6, CF3, alcoxiC1-6alquilo (C1-6), alcoxiC1-6, OCF3, alcoxiC1-6 alcoxi(C1-6), alquiltioC1-6, alqueniloC2-6, alquiniloC2-6, cicloalquiloC3-10 (así mismo opcionalmente sustituido por alquiloC1-4 u oxo), metilenedioxi, difluorometilenedioxi, fenil, fenilalquil (C1-4), fenoxi, feniltio, fenil alcoxi(C1-4), heteroaril, heteroaril alquil(C1-4), heteroariloxi o heteroarilalcoxi (C1-4); en donde cualquiera de las mitades fenil y heteroaril inmediatamente anteriores están opcionalmente sustituidas con halógeno, hidroxi, nitro, S(O)q(alquiloC1-4), S(O)2NH2, ciano, alquiloC1-4, alcoxiC1-4, C(O)NH2, C(O)NH(alquiloC1-4), CO2H, CO2(alquiloC1-4), NHC(O)(alquiloC1-4), NHS(O)2(alquiloC1-4), C(O)(alquilo C1-4), CF3 u OCF3;p y q son independientemente 0, 1 o 2;R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R19, R20, R21, R22, y R23 son independientemente, hidrógeno, alquiloC1-6 (opcionalmente substituido por halógeno, hidroxi o cicloalquilo C3-10), CH2(alquenilo C2-6), fenil (opcionalmente sustituido así mismo por halógeno, hidroxi, nitro, NH2, NH(alquilo C1-4), N(alquiloC1-4)2, S(O)2(alquiloC1-4), S(O)2NH2, S(O)2NH(alquiloC1-4), S(O)2N(alquiloC1-4)2, ciano, alquiloC1-4, alcoxiC1-4, C(O)NH2, C(O)NH(alquilo C1-4), CO2H, CO2(alquiloC1-4), NHC(O)(alquiloC1-4), NHS(O)2(alquiloC1-4), C(O)(alquilo C1-4), CF3 u OCF3) o heterociclilo (opcionalmente substituido a sí mismo por halógeno, hidroxi, nitro, NH2, NH (alquiloC1-4), ....
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0116179A GB0116179D0 (en) | 2001-07-02 | 2001-07-02 | Chemical compounds |
| GB0123037A GB0123037D0 (en) | 2001-09-25 | 2001-09-25 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5540307A2 true CO5540307A2 (es) | 2005-07-29 |
Family
ID=26246268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03112957A CO5540307A2 (es) | 2001-07-02 | 2003-12-29 | Derivados de piperidina utiles como moduladores de la activi dad del receptor de quimoquina |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7307090B2 (es) |
| EP (2) | EP1404667B1 (es) |
| JP (1) | JP3857270B2 (es) |
| KR (1) | KR20040013090A (es) |
| CN (1) | CN1545509A (es) |
| AR (1) | AR042401A1 (es) |
| AT (1) | ATE319703T1 (es) |
| BR (1) | BR0210733A (es) |
| CA (1) | CA2452597A1 (es) |
| CO (1) | CO5540307A2 (es) |
| CY (1) | CY1106095T1 (es) |
| DE (1) | DE60209736T2 (es) |
| DK (1) | DK1404667T3 (es) |
| ES (1) | ES2258642T3 (es) |
| HK (1) | HK1062559A1 (es) |
| HU (1) | HUP0401886A2 (es) |
| IL (1) | IL159256A0 (es) |
| IS (1) | IS7094A (es) |
| MX (1) | MXPA03011722A (es) |
| NO (1) | NO20035729L (es) |
| NZ (1) | NZ530202A (es) |
| PL (1) | PL368041A1 (es) |
| PT (1) | PT1404667E (es) |
| RU (1) | RU2004100839A (es) |
| SA (1) | SA02230184B1 (es) |
| WO (1) | WO2003004487A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| WO2003059965A1 (en) * | 2002-01-10 | 2003-07-24 | University Of Washington | Hydrogels formed by non-covalent linkages |
| AU2003209388A1 (en) * | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| SE0200844D0 (sv) * | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| US7030115B2 (en) * | 2002-03-21 | 2006-04-18 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| WO2003080586A1 (en) * | 2002-03-21 | 2003-10-02 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| PE20040167A1 (es) | 2002-03-28 | 2004-05-26 | Novartis Ag | Amidas del acido sulfamico |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| US20040192738A1 (en) * | 2003-03-18 | 2004-09-30 | Aventis Pharma Deutschland Gmbh | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it |
| SE0300957D0 (sv) * | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
| SE0400925D0 (sv) * | 2004-04-06 | 2004-04-06 | Astrazeneca Ab | Chemical compounds |
| SE0403003D0 (sv) * | 2004-12-09 | 2004-12-09 | Astrazeneca Ab | Chemical compound 1 |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006071958A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006126948A1 (en) * | 2005-05-27 | 2006-11-30 | Astrazeneca Ab | Piperidines for the treatment of chemokine mediated diseases |
| TW200722419A (en) * | 2005-05-27 | 2007-06-16 | Astrazeneca Ab | Chemical compounds |
| KR20080037655A (ko) * | 2005-07-21 | 2008-04-30 | 아스트라제네카 아베 | 신규 피페리딘 유도체 |
| EP1957076A2 (en) * | 2005-11-29 | 2008-08-20 | Merck & Co., Inc. | Thiazole derivatives as cxcr3 receptor modulators |
| BRPI0707623A2 (pt) * | 2006-02-10 | 2011-05-10 | Janssen Pharmaceutica Nv | derivados de piperidina como antagonistas de receptores de cxcr3 |
| CN101378756A (zh) * | 2006-02-10 | 2009-03-04 | 詹森药业有限公司 | 作为cxcr3受体拮抗剂的哌啶衍生物 |
| ES2499018T3 (es) * | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
| KR101551998B1 (ko) | 2008-12-03 | 2015-09-09 | 더 스크립스 리서치 인스티튜트 | 줄기 세포 배양 |
| EP3297438B1 (en) | 2015-05-21 | 2021-10-20 | ChemoCentryx, Inc. | Ccr2 modulators |
| EP3687525A4 (en) | 2017-09-25 | 2021-10-13 | ChemoCentryx, Inc. | POLYTHERAPY USING A CHEMIOKIN RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 / PD-L1 INHIBITOR |
| CN112105353B (zh) | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| TWI730297B (zh) * | 2018-02-27 | 2021-06-11 | 日商組合化學工業股份有限公司 | 巰基酚化合物的製造方法及巰基酚化合物的中間體 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1250719A (es) | 1969-03-19 | 1971-10-20 | ||
| US4556660A (en) | 1982-07-12 | 1985-12-03 | Janssen Pharmaceutica N.V. | N-(Bicyclic heterocyclyl)-4-piperidinamines |
| DK139684A (da) | 1983-04-11 | 1984-10-12 | Janssen Pharmaceutica Nv | N-aryl-alpha-amino-carboxamider |
| US4634704A (en) | 1983-10-06 | 1987-01-06 | Janssen Pharmaceutica, N.V. | Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines |
| US4695575A (en) | 1984-11-13 | 1987-09-22 | Janssen Pharmaceutica, N.V. | 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines |
| PH23995A (en) | 1984-01-09 | 1990-02-09 | Janssen Pharmaceutica Nv | 4((bicycle heterocyclyl)-methyl and hetero)piperidines |
| US4588722A (en) | 1984-01-09 | 1986-05-13 | Janssen Pharmaceutica N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives |
| EP0542363A3 (en) | 1991-11-14 | 1993-07-14 | Glaxo Group Limited | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation |
| GB9319534D0 (en) | 1993-09-22 | 1993-11-10 | Boots Co Plc | Therapeutic agents |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| WO1996041631A1 (en) | 1995-06-09 | 1996-12-27 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| NZ333513A (en) | 1996-07-10 | 2000-04-28 | Schering Corp | 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists |
| US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| EP0821954A1 (en) | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating mental retardation |
| US5977138A (en) | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
| HUP9904363A3 (en) * | 1996-08-15 | 2000-12-28 | Schering Corp | Piperidine ether muscarinic antagonists and pharmaceutical compositions containing them |
| DE59711622D1 (de) | 1996-09-10 | 2004-06-17 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| PL342243A1 (en) | 1998-01-27 | 2001-06-04 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclic inhibitors of the factor xa |
| EP1052992A1 (en) | 1998-02-02 | 2000-11-22 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| TWI245763B (en) | 1998-04-02 | 2005-12-21 | Janssen Pharmaceutica Nv | Biocidal benzylbiphenyl derivatives |
| CN1118452C (zh) | 1998-04-28 | 2003-08-20 | 大日本制药株式会社 | 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体 |
| US6066636A (en) | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
| CN1146559C (zh) | 1998-06-30 | 2004-04-21 | 先灵公司 | 毒蕈碱性拮抗剂 |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| JP2003529531A (ja) | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルＸａ因子阻害剤 |
| US6331545B1 (en) | 1998-12-18 | 2001-12-18 | Soo S. Ko | Heterocycyclic piperidines as modulators of chemokine receptor activity |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| TR200402496T2 (tr) | 1999-05-04 | 2005-01-24 | Schering Corporation | CCR5 antagonistleri olarak yararlı piperidin türevleri. |
| SE9902551D0 (sv) | 1999-07-02 | 1999-07-02 | Astra Pharma Prod | Novel compounds |
| KR20020087041A (ko) | 1999-07-28 | 2002-11-21 | 아벤티스 파마슈티칼스 프로덕츠 인크. | 치환된 옥소아자헤테로사이클릴 화합물 |
| IT1307809B1 (it) | 1999-10-21 | 2001-11-19 | Menarini Ricerche Spa | Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono. |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
| GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| GB0107907D0 (en) | 2001-03-29 | 2001-05-23 | Smithkline Beecham Plc | Novel compounds |
| CZ20032636A3 (cs) | 2001-03-29 | 2003-12-17 | Schering Corporation | Látky antagonizující CCR5 |
| GB0108876D0 (en) | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| AR036366A1 (es) | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0202838D0 (sv) | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| SE0300850D0 (sv) | 2003-03-25 | 2003-03-25 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0301368D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| KR20060009390A (ko) | 2003-06-13 | 2006-01-31 | 쉐링 악티엔게젤샤프트 | Ｃｃｒ-５ 길항제로서의 퀴놀릴 아미드 유도체 |
-
2002
- 2002-07-01 RU RU2004100839/04A patent/RU2004100839A/ru not_active Application Discontinuation
- 2002-07-01 EP EP02747793A patent/EP1404667B1/en not_active Expired - Lifetime
- 2002-07-01 JP JP2003510654A patent/JP3857270B2/ja not_active Expired - Fee Related
- 2002-07-01 DK DK02747793T patent/DK1404667T3/da active
- 2002-07-01 IL IL15925602A patent/IL159256A0/xx unknown
- 2002-07-01 MX MXPA03011722A patent/MXPA03011722A/es active IP Right Grant
- 2002-07-01 PL PL02368041A patent/PL368041A1/xx not_active Application Discontinuation
- 2002-07-01 AT AT02747793T patent/ATE319703T1/de not_active IP Right Cessation
- 2002-07-01 EP EP05018449A patent/EP1604982A1/en not_active Withdrawn
- 2002-07-01 US US10/480,625 patent/US7307090B2/en not_active Expired - Fee Related
- 2002-07-01 KR KR10-2004-7000023A patent/KR20040013090A/ko not_active Application Discontinuation
- 2002-07-01 CA CA002452597A patent/CA2452597A1/en not_active Abandoned
- 2002-07-01 PT PT02747793T patent/PT1404667E/pt unknown
- 2002-07-01 ES ES02747793T patent/ES2258642T3/es not_active Expired - Lifetime
- 2002-07-01 BR BR0210733-3A patent/BR0210733A/pt not_active IP Right Cessation
- 2002-07-01 HU HU0401886A patent/HUP0401886A2/hu unknown
- 2002-07-01 CN CNA028162714A patent/CN1545509A/zh active Pending
- 2002-07-01 DE DE60209736T patent/DE60209736T2/de not_active Expired - Lifetime
- 2002-07-01 WO PCT/SE2002/001311 patent/WO2003004487A1/en active IP Right Grant
- 2002-07-01 NZ NZ530202A patent/NZ530202A/en unknown
- 2002-07-02 SA SA02230184A patent/SA02230184B1/ar unknown
- 2002-07-02 AR ARP020102488A patent/AR042401A1/es not_active Application Discontinuation
-
2003
- 2003-12-19 NO NO20035729A patent/NO20035729L/no not_active Application Discontinuation
- 2003-12-29 CO CO03112957A patent/CO5540307A2/es not_active Application Discontinuation
- 2003-12-30 IS IS7094A patent/IS7094A/is unknown
-
2004
- 2004-07-22 HK HK04105447A patent/HK1062559A1/xx not_active IP Right Cessation
-
2006
- 2006-06-07 CY CY20061100755T patent/CY1106095T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1404667T3 (da) | 2006-07-10 |
| CY1106095T1 (el) | 2011-06-08 |
| US7307090B2 (en) | 2007-12-11 |
| JP3857270B2 (ja) | 2006-12-13 |
| ATE319703T1 (de) | 2006-03-15 |
| AR042401A1 (es) | 2005-06-22 |
| HUP0401886A2 (hu) | 2004-12-28 |
| HK1062559A1 (en) | 2004-11-12 |
| NO20035729D0 (no) | 2003-12-19 |
| MXPA03011722A (es) | 2004-03-19 |
| WO2003004487A1 (en) | 2003-01-16 |
| US20040235894A1 (en) | 2004-11-25 |
| SA02230184B1 (ar) | 2007-03-25 |
| EP1604982A1 (en) | 2005-12-14 |
| IL159256A0 (en) | 2004-06-01 |
| PL368041A1 (en) | 2005-03-21 |
| EP1404667B1 (en) | 2006-03-08 |
| ES2258642T3 (es) | 2006-09-01 |
| DE60209736D1 (de) | 2006-05-04 |
| KR20040013090A (ko) | 2004-02-11 |
| NZ530202A (en) | 2005-06-24 |
| CA2452597A1 (en) | 2003-01-16 |
| RU2004100839A (ru) | 2005-06-20 |
| CN1545509A (zh) | 2004-11-10 |
| IS7094A (is) | 2003-12-30 |
| JP2004536112A (ja) | 2004-12-02 |
| EP1404667A1 (en) | 2004-04-07 |
| BR0210733A (pt) | 2004-07-20 |
| DE60209736T2 (de) | 2006-11-02 |
| PT1404667E (pt) | 2006-07-31 |
| NO20035729L (no) | 2004-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5540307A2 (es) | Derivados de piperidina utiles como moduladores de la activi dad del receptor de quimoquina | |
| HRP20080113T3 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
| CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
| ATE368655T1 (de) | Stickstoffhaltige heterocyclische verbindung und arzneimittel davon | |
| CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
| CY1110399T1 (el) | Ρυθμιστες της τετραϋδροπυρανυλο κυκλοπεντυλο τετραϋδροπυριδοπυριδινης για την ενεργοτητα των υποδοχεων των χημειοκινων | |
| ECSP034720A (es) | Derivado de isoxazolina y herbicida que lo contiene como ingrediente activo | |
| PE20040590A1 (es) | Composiciones de pirrolotriazina anilina como inhibidores de cinasa | |
| EA200300428A1 (ru) | Антагонисты метаботропных рецепторов глутамата | |
| ATE461188T1 (de) | Verstärker von glutamat-rezeptoren | |
| CO5611135A2 (es) | Nuevos derivados de piperidina como moduladores de la actividad de quimioquina, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| ATE357142T1 (de) | 7-aminotriazolopyrimidine zur bekämpfung von schadpilzen | |
| HUP0402679A2 (hu) | Pirrolidin- és piperidin-származékok mint NK1 antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények | |
| AR057433A1 (es) | Compuestos quimicos derivados de piridopirimidina, un metodo para su preparacion y composicion farmaceutica | |
| DK1663989T3 (da) | Krystallisk form af bis(E)-7-[4(4-fluorphenyl)-6-isopropyl-2-methyl(methylsulfonyl)aminopyrimidin-5-yl(3R,5S))-3-5-dihydroxyhept-6-ensyrecalciumsalt | |
| DE602004031722D1 (de) | Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden | |
| MY148980A (en) | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof | |
| ATE515262T1 (de) | Verwendung von parthenolid-derivaten als antileukämische und zytotoxische mittel | |
| MY136824A (en) | Substituted benzoxazinones and uses thereof | |
| AR029343A1 (es) | USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN | |
| ATE277042T1 (de) | Antimikrobielle 4-oxochinolizine mit 2- pyridongerüsten als teilstruktur | |
| MXPA05009523A (es) | Derivados de quinolina/benzoxazinona y sus usos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |